2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C)

2.1 Essential Documents Before, During, and After Trial (ICH E6(R3) Appendix C)

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Appendix C, Essential Records for the Conduct of a Clinical Trial — note the rename from "essential documents", which makes the requirement media-neutral.

ACRP-CP Exam Focus: Essential documents serve two primary functions: they demonstrate the compliance of the investigator, sponsor, and monitor with Good Clinical Practice (GCP) standards and applicable regulatory requirements, and they allow for the independent evaluation and reconstruction of trial conduct and data integrity. On the exam, expect scenario-based questions asking where specific documents belong (Sponsor TMF vs. Investigator Site File), what triggers mandatory updates (e.g., protocol amendments, new sub-investigators), and who holds legal custody of participant-identifying records.

1. Regulatory Foundation & Purpose of Essential Documents

Under ICH GCP E6(R3) Appendix C.1, essential documents are defined as:

$\text{Essential Documents} = \text{Records that individually and collectively permit evaluation of trial conduct and data quality}$

These documents provide the audit trail that enables both independent auditors (representing the sponsor) and regulatory inspectors (such as FDA BIMO, EMA, or MHRA) to verify that:

1. The rights, safety, and well-being of trial subjects were protected.
2. The trial was conducted in accordance with the approved protocol, ICH GCP, and applicable statutory regulations.
3. The data generated are authentic, complete, verifiable, and scientifically robust.

Filing essential documents in a timely and organized manner across the Investigator Site File (ISF) and the Sponsor Trial Master File (TMF) is a fundamental operational responsibility. An incomplete or poorly maintained document repository is one of the most frequent root causes of regulatory inspection findings, Form FDA 483 observations, and trial delays.

2. Stage 1: Before the Clinical Phase Begins (Pre-Trial Documents)

Before a trial can initiate screening or enroll its first subject, a comprehensive set of foundational documents must be established, approved, and filed. ICH E6(R3) Appendix C.2 specifies the pre-trial documents required to confirm that the site is qualified, the protocol is ethically and scientifically vetted, and proper regulatory clearances have been granted.

Comprehensive Breakdown of Pre-Trial Essential Documents

+---------------------------------------------------------------------------------------------+
|                                CRITICAL COMPLIANCE DISTINCTION                              |
|                                                                                             |
| Form FDA 1572 is a binding legal contract with the U.S. FDA required for studies conducted  |
| under a U.S. Investigational New Drug (IND) application.                                     |
| Key Commitments on the 1572 include:                                                        |
| 1. Personally conduct or supervise the investigation.                                       |
| 2. Ensure all associates, colleagues, and employees assisting are informed of obligations. |
| 3. Maintain adequate and accurate records (ALCOAC standards).                               |
| 4. Report adverse experiences to the sponsor in accordance with 21 CFR 312.64.              |
| 5. Ensure the IRB complies with 21 CFR Part 56 and initial/continuing approvals are secured. |
+---------------------------------------------------------------------------------------------+

3. Stage 2: During the Conduct of the Trial (Active Trial Documents)

During trial execution, essential documents capture the dynamic operations of the trial, ensuring that all modifications to the protocol, participant safety signals, drug accountability, and monitoring oversight are contemporaneously recorded.

Essential Documents Generated During Trial Execution

                       ACTIVE TRIAL ESSENTIAL DOCUMENTS
  +--------------------------+--------------------------+--------------------------+
  |   REGULATORY & ETHICAL   |    SAFETY & MONITORING   |    SUBJECT & PRODUCT     |
  +--------------------------+--------------------------+--------------------------+
  | * Protocol Amendments    | * SAE Reports & CIOMS    | * Signed Consent Forms   |
  | * Revised ICF Approvals  | * IND Safety Reports     | * IP Accountability Logs |
  | * Continuing IRB Reviews | * IMV Monitoring Reports | * Screening/Enrollment   |
  | * Updated CVs & Licenses | * CRA Follow-Up Letters  | * Subject ID Code List   |
  | * Delegation Log Updates | * Action Item Trackers   | * Source Docs & eCRFs    |
  +--------------------------+--------------------------+--------------------------+

Key Operational Documentation Requirements:

1. Protocol Amendments & Informed Consent Revisions:

   • Whenever a protocol amendment is issued that alters subject safety, trial design, or study procedures, it must receive written IRB/IEC approval and, where required, Regulatory Authority approval before implementation at the site (unless necessary to eliminate immediate hazards to participants under ICH E6(R3) Annex 1 2.5.4–2.5.5 / 21 CFR 312.66).
   • Revised Informed Consent Forms (ICFs) must be submitted to and approved by the IRB. Once approved, currently enrolled active participants must be re-consented using the updated version at their next scheduled visit or earlier if safety information dictates.

2. Staff Additions & Delegation of Authority Updates:

   • When new sub-investigators or coordinators join the study, their CV, professional medical license, and GCP/protocol training records must be collected and filed prior to their performing any study-related tasks.
   • The Delegation of Authority Log (DOAL) must be updated, signed, and dated by the Principal Investigator. For IND studies, if a new Sub-Investigator is added, Form FDA 1572 must be updated (or documented on an annual update per sponsor SOP).

3. Safety Notifications & Expedited Reports:

   • Sites must document all Adverse Events (AEs) in source records and report all Serious Adverse Events (SAEs) to the sponsor within 24 hours of awareness.
   • Sponsors must distribute IND Safety Reports / Suspected Unexpected Serious Adverse Reactions (SUSARs) to all participating investigators across all active sites. Investigators must file these in the ISF and submit them to their local IRB per the IRB's written reporting policies.

4. Investigational Product (IP) Accountability Records:

   • Continuous tracking of IP receipt, storage condition monitoring (daily temperature logs, minimum/maximum thermometers, continuous data loggers), dispensing to subjects, returns from subjects, and reconciliation.
   • Temperature excursions must be immediately quarantined and documented with sponsor technical assessments filed in the ISF and TMF.

5. Subject Identification Code List:

   • A confidential master key linking subject screening/enrollment ID numbers to subject full names, medical record numbers, and contact details.
   • MUST BE KEPT SECURELY AT THE SITE ONLY. Monitors and auditors may inspect it on-site for source data verification, but it is strictly forbidden from being copied, photographed, or uploaded into the sponsor TMF.

4. Stage 3: After Completion or Termination of the Trial (Post-Trial Documents)

Once the last subject completes their final follow-up visit (LPLV - Last Patient Last Visit) or if the trial is terminated prematurely, close-out activities commence to ensure all trial materials are reconciled, data is locked, and regulatory obligations are finalized.

Post-Trial Essential Documents Inventory

5. Real-World Case Scenario: The Protocol Amendment Cascade

+------------------------------------------------------------------------------------------------+
|                                 SCENARIO: PROTOCOL AMENDMENT CASCADE                           |
|                                                                                                |
| Context: Protocol Phase III Oncology Trial - Protocol Amendment 03 is issued by the sponsor     |
| introducing a revised dosing schedule due to new pharmacodynamic data and updating the risk   |
| section regarding potential QT prolongation.                                                   |
|                                                                                                |
| Step 1: Sponsor submits Amendment 03 and revised ICF to Regulatory Authority & central IRB.    |
| Step 2: Site receives sponsor-approved amendment package; local IRB submits review.            |
| Step 3: Site receives documented IRB approval for Amendment 03 and revised ICF Version 4.0.    |
| Step 4: Site staff complete protocol-specific retraining on the new dosing schedule.           |
| Step 5: Retraining is documented on the Site Training Log BEFORE dosing any subject under Amd 3.|
| Step 6: When Subject 104 arrives for Cycle 4 Visit, CRC administers ICF V4.0. Subject signs    |
|         prior to undergoing ECG or receiving IP under the revised dosing schedule.             |
| Step 7: CRC files IRB approval letter, approved ICF, training record in ISF, and original ICF  |
|         in subject's confidential research binder.                                             |
+------------------------------------------------------------------------------------------------+